This is just a gamble like most other early stage bio companies. There would be a lot like myself stuck with an average multiples higher than what it is atm. Good results still won’t get me back near my average. Not sure anybody would have any idea whether the results could be good or bad. Let’s hope they are positive
Ann: Phase 2a/b clinical trial update, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
